Regular Use Effect of Inhaled Ipratropium Bromide on Airway Responsiveness to Methacholine in Well-controlled Asthma
Primary Purpose
Asthma
Status
Completed
Phase
Phase 4
Locations
Canada
Study Type
Interventional
Intervention
Ipratropium Metered Dose Inhaler
placebo metered dose inhaler
Sponsored by

About this trial
This is an interventional treatment trial for Asthma focused on measuring ipratropium bromide, methacholine PD20, tolerance
Eligibility Criteria
Inclusion Criteria:
- airway responsiveness to methacholine
- adequate baseline lung function
- no respiratory infection or exposure to stimuli that may alter response to methacholine within 4 weeks
Exclusion Criteria:
- pregnancy
- current smoker
- requirement for medications other than salbutamol that will interfere with airway response to methacholine
Sites / Locations
- University of Saskatchewan
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Placebo Comparator
Arm Label
Ipratropium bromide
placebo
Arm Description
20mcg bronchodilator inhaler
matching bronchodilator inhaler
Outcomes
Primary Outcome Measures
Methacholine PD20
dose of methacholine required to induce a 20% fall in FEV1 (volume of air forcefully exhaled in one second)
Methacholine PD20
dose of methacholine required to induce a 20% fall in FEV1 (volume of air forcefully exhaled in one second)
Methacholine PD20
dose of methacholine required to induce a 20% fall in FEV1 (volume of air forcefully exhaled in one second)
Secondary Outcome Measures
Full Information
NCT ID
NCT04167280
First Posted
November 13, 2019
Last Updated
March 25, 2020
Sponsor
University of Saskatchewan
1. Study Identification
Unique Protocol Identification Number
NCT04167280
Brief Title
Regular Use Effect of Inhaled Ipratropium Bromide on Airway Responsiveness to Methacholine in Well-controlled Asthma
Official Title
Regular Use Effect of Inhaled Ipratropium Bromide on Airway Responsiveness to Methacholine in Well-controlled Asthma
Study Type
Interventional
2. Study Status
Record Verification Date
March 2020
Overall Recruitment Status
Completed
Study Start Date
November 5, 2019 (Actual)
Primary Completion Date
March 13, 2020 (Actual)
Study Completion Date
March 13, 2020 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University of Saskatchewan
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
Study is looking at the development of tolerance to methacholine following regular use of ipratropium bromide in mild asthmatics.
Detailed Description
This study is being conducted people with well controlled (mild) asthma to determine if ipratropium bromide taken three times daily for six days (i.e. 2 puffs in the morning, 2 puffs in the afternoon and 2 puffs in the evening) followed by a final dose on the morning of day 7 reduces the effectiveness of this medication on blocking the effect of methacholine challenge.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Asthma
Keywords
ipratropium bromide, methacholine PD20, tolerance
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Crossover Assignment
Masking
ParticipantInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
12 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Ipratropium bromide
Arm Type
Active Comparator
Arm Description
20mcg bronchodilator inhaler
Arm Title
placebo
Arm Type
Placebo Comparator
Arm Description
matching bronchodilator inhaler
Intervention Type
Drug
Intervention Name(s)
Ipratropium Metered Dose Inhaler
Intervention Description
MDI to deliver 20mcg per puff ipratropium bromide
Intervention Type
Drug
Intervention Name(s)
placebo metered dose inhaler
Intervention Description
matched MDI to deliver inactive drug
Primary Outcome Measure Information:
Title
Methacholine PD20
Description
dose of methacholine required to induce a 20% fall in FEV1 (volume of air forcefully exhaled in one second)
Time Frame
Pre treatment
Title
Methacholine PD20
Description
dose of methacholine required to induce a 20% fall in FEV1 (volume of air forcefully exhaled in one second)
Time Frame
Day 7 after starting treatment
Title
Methacholine PD20
Description
dose of methacholine required to induce a 20% fall in FEV1 (volume of air forcefully exhaled in one second)
Time Frame
24 hours after last dose
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
airway responsiveness to methacholine
adequate baseline lung function
no respiratory infection or exposure to stimuli that may alter response to methacholine within 4 weeks
Exclusion Criteria:
pregnancy
current smoker
requirement for medications other than salbutamol that will interfere with airway response to methacholine
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Don Cockcroft, MD
Organizational Affiliation
University of Saskatchewan
Official's Role
Principal Investigator
Facility Information:
Facility Name
University of Saskatchewan
City
Saskatoon
State/Province
Saskatchewan
ZIP/Postal Code
S7N 0W8
Country
Canada
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
Regular Use Effect of Inhaled Ipratropium Bromide on Airway Responsiveness to Methacholine in Well-controlled Asthma
We'll reach out to this number within 24 hrs